Table 1.
Baseline characteristics of the patients included in the study n (%)
| Population characteristics (n = 106) | Value |
| Male gender | 47 (44) |
| Age - mean | 40 ± 13 yr |
| Median time between diagnosis and VCE | 5.5 (IQR 2-10) yr |
| Montreal classification | |
| Age at diagnosis | |
| A1: Below 17 | 7 (7) |
| A2: 17-40 | 84 (79) |
| A3: Above 40 | 15 (14) |
| Behavior | |
| B1: Non-stenosing/non-penetrating | 86 (81) |
| B2: Stenosing | 12 (11) |
| B3: Penetrating | 8 (8) |
| Location | |
| L1: Terminal ileum | 74 (70) |
| L2: Colonic | 10 (9) |
| L3: Ileocolonic | 22 (21) |
| + L4: Upper disease | 38 (36) |
| Treatment before VCE | |
| Anti-TNF | 21 (20) |
| Immunosuppressors | 38 (36) |
| Aminosalicylates only | 40 (38) |
| No treatment | 7 (6) |
VCE: Video capsule endoscopy; TNF-α: Tumor necrosis factor α.